You are here

VRTX

$161.91

+2.49%

Investor Relations

News & Events

Filter Releases
 
Press Releases
Date Title and Summary View
Feb 4, 2010
CAMBRIDGE, Mass., Feb 04, 2010 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today provided an update on recent progress in its late-stage development programs in hepatitis C virus (HCV) infection and cystic fibrosis (CF), reported consolidated financial results for the year ended December 31,...
Apr 21, 2010
CAMBRIDGE, Mass., Apr 21, 2010 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today provided an update on recent progress in its development programs in hepatitis C virus (HCV) infection, cystic fibrosis (CF) and other diseases and reported consolidated financial results for the quarter ended M...
Jul 28, 2010
CAMBRIDGE, Mass., Jul 28, 2010 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today provided an update on recent progress in its development programs in hepatitis C virus (HCV) infection, cystic fibrosis (CF) and other diseases and reported consolidated financial results for the quarter ended J...
Oct 25, 2010
CAMBRIDGE, Mass., Oct 25, 2010 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reviewed recent business and clinical progress and reported consolidated financial results for the quarter ended September 30, 2010. "With the recent completion of our Phase 3 registration program for telaprevi...
Feb 3, 2011
-Hepatitis C: Regulatory agencies in U.S., Europe and Canada to provide accelerated reviews of telaprevir applications- -Cystic Fibrosis: First Phase 3 registration data for VX-770 expected in first quarter 2011; potential regulatory submissions in the U.S. and E.U. in second half of 2011- ...
May 3, 2011
-Hepatitis C: FDA decision on NDA for INCIVEKTM (telaprevir) expected this month- -Cystic Fibrosis: Phase 3 program for VX-770 supports applications for approval in U.S. and E.U., with NDA and MAA planned for second half of 2011- -Financial: Vertex enters second quarter wi...
Jul 28, 2011
-Quarter highlighted by approval and launch of INCIVEKTM for hepatitis C and completion of VX-770 Phase 3 program in cystic fibrosis- -Continued progress in advancing new combinations of medicines for the future treatment of hepatitis C and cystic fibrosis- CAMBRIDGE...
Oct 27, 2011
-$420 million in net product revenues for INCIVEK for the first full quarter since launch- -Continued strength in launch of INCIVEK for hepatitis C; submissions of KALYDECOTM (VX-770, ivacaftor) approval applications complete- CAMBRIDGE, Mass.--(BUSINESS WIRE)-- ...
Feb 2, 2012
-Successful launch of INCIVEK (telaprevir) for hepatitis C and recent approval of KALYDECO (ivacaftor) for cystic fibrosis position Vertex for continued growth, earnings and cashflow- CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today report...
Apr 26, 2012
-Approximately 600 people with cystic fibrosis have started treatment with KALYDECO since approval on January 31- -Multiple ongoing clinical trials to generate data beginning in second quarter, including study of KALYDECO combined with VX-809 in cystic fibrosis and first data for Alios nucleotides...
Jul 30, 2012
-Second quarter 2012 total revenues of $418 million, including second quarter 2012 net product revenues of approximately $328 million for INCIVEK in hepatitis C and $46 million for KALYDECO in cystic fibrosis; company revises financial guidance for full-year 2012 INCIVEK net revenues- -Cy...
Nov 1, 2012
-Third quarter 2012 total revenues of $336 million, including third quarter 2012 net product revenues of approximately $254 million for INCIVEK in hepatitis C and $49 million for KALYDECO in cystic fibrosis- -Cystic Fibrosis: Three ongoing Phase 3 label expansion studies for ivacaftor monotherapy;...
Jan 29, 2013
-2013 investment focused on key development programs in cystic fibrosis, hepatitis C and autoimmune diseases- -Full-year 2012 revenues of $1.53 billion, including net product revenues of $1.16 billion for INCIVEK in hepatitis C and $171.6 million for KALYDECO in cystic fibrosis- ...
Apr 30, 2013
-First quarter 2013 total revenues of $328 million, including net product revenues of $206 million for INCIVEK in hepatitis C and $62 million for KALYDECO in cystic fibrosis- -Cystic fibrosis: Enrollment ongoing in Phase 3 program for VX-809 in combination with ivacaftor for people with two copies...
Jul 29, 2013
-Second quarter 2013 total revenues of $311 million, including net product revenues of $99 million for KALYDECO in cystic fibrosis and $156 million for INCIVEK in hepatitis C; cash position of approximately $1.43 billion on June 30, 2013- -Data from Phase 3 study of ivacaftor monotherapy support s...